#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-8160f282-6d7e-48b7-b35b-bfc4314a8ad9: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-5d7da27f-0e7b-48ef-ad5f-c8c44c5b66f3: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Vascepa

Vascepa

Dec 17, 2019

Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval

Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation. Duchenne Muscular Dystrophy is a progressive worsening of the skeletal and heart muscles resulting in weakness. The disorder, is due to deficient prot...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles

Feb 12, 2025

Newsletter/Whitepaper

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Vascepa

Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval

Editor Picks